law.justia.com/cases/federal/appellate-courts/ca2/14-4774/14-4774-2016-05-17.html

Plaintiff alleged that Pfizer, his former employer, improperly marketed Lipitor as ... are incorporated into and made mandatory by the drug's label; and Pfizer thus ...

www.lexology.com/library/detail.aspx?g=d431f023-77cd-4390-b8aa-d14fa29eb491

Nov 27, 2012 ... Polansky v. Pfizer, Inc., 2012 U.S. Dist. LEXIS 163557 (E.D.N.Y. Nov. 15, 2012), issued a decision distinguishing between unlawful “off-label” ...

www.fdalawblog.net/2016/05/second-circuit-affirms-dismissal-of-off-label-promotion-case-that-was-brought-under-the-false-claims

May 24, 2016 ... Polansky v. ... Polansky alleged that Pfizer, Inc. (“Pfizer” or the “Company”) violated the FCA by off‑label marketing its cholesterol‑lowering drug, ...

www.akingump.com/en/news-insights/false-claims-act-circuit-splits-fca-issues-that-may-soon-reach.html

Feb 12, 2018 ... Hyatt v. Northrop Corp., that relators may invoke equitable tolling if the relator did not ..... Pfizer, Inc., in 2016, summarized the split as follows: ... of actual false claims presented to the government (which Polansky does not do).

www.druganddevicelawblog.com/2016/06/a-blow-against-false-claims-act-liability-for-off-label-promotion.html

Jun 2, 2016 ... Polansky v. Pfizer, Inc., No. 14-4774, 2016 U.S. App. Lexis 8974 (2d Cir. May 17, 2016), we could be lazy and swap in “a panel” for “a judge” in ...

caselaw.findlaw.com/us-1st-circuit/1024622.html

Case opinion for US 1st Circuit UNITED STATES ROST v. PFIZER INC. Read the Court's full decision on FindLaw.

www.insidethefca.com/fca-issues-to-watch-pharmaceutical-and-device-developments

May 15, 2017 ... Pfizer, Inc., 2016 WL 3017381 (D. Mass. May 23, 2016), after six years and five amended complaints, Pfizer was awarded ... Polansky v. Pfizer ...

www.opn.ca6.uscourts.gov/opinions.pdf/17a0240p-06.pdf

Oct 27, 2017 ... No. 16-3154. U.S. ex rel. Ibanez v. Bristol-Myers Squibb, et. al. Page 2 ..... Polansky v. Pfizer, Inc., 822 F.3d 613, 619–20 (2d Cir. 2016).

www.mintz.com/insights-center/viewpoints/2146/2017-02-fda-hardens-its-stance-intended-use-and-label-use-and

Feb 17, 2017 ... In 2016, two qui tam cases involving off-label claims—U.S. ex rel. Colquitt v. Abbott Laboratories and U.S. ex rel. Polansky v. Pfizer, Inc.—were ...